Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Ototoxicity

ClinicalTrials.gov lists 49 trials for Ototoxicity or a narrower condition beneath it.

MeSH D000081015 Otorhinolaryngologic Diseases C09 C23 C25 C26
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 2 Phase 1/2 Phase 1/2 2 Phase 2 Phase 2 10 Phase 2/3 Phase 2/3 2 Phase 3 Phase 3 3 Phase 4 Phase 4 2 Not applicable Not applicable 14 Observational Observational 14 Phase 1 Phase 1 2 Phase 1/2 Phase 1/2 2 Phase 2 Phase 2 10 Phase 2/3 Phase 2/3 2 Phase 3 Phase 3 3 Phase 4 Phase 4 2 Not applicable Not applicable 14 Observational Observational 14

Trials per phase

49 of the 49 trials are tagged with Ototoxicity itself; the rest are tagged with a narrower condition beneath it.

Get the Ototoxicity report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Ototoxicity trials start? (17)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 7

2007: 4 trials (Observational 1, Phase 3 1, Phase 2/3 1, Phase 2 1) 2008: 6 trials (Observational 1, Not applicable 1, Phase 3 2, Phase 2 1, Phase 1/2 1) 2010: 2 trials (Observational 1, Phase 2/3 1) 2011: 5 trials (Observational 3, Not applicable 1, Phase 4 1) 2013: 1 trials (Phase 2 1) 2014: 1 trials (Not applicable 1) 2015: 3 trials (Observational 1, Not applicable 2) 2016: 1 trials (Not applicable 1) 2017: 1 trials (Phase 2 1) 2019: 1 trials (Phase 2 1) 2020: 2 trials (Phase 2 1, Phase 1 1) 2021: 2 trials (Observational 1, Phase 4 1) 2022: 1 trials (Not applicable 1) 2023: 6 trials (Observational 2, Not applicable 3, Phase 1 1) 2024: 7 trials (Observational 2, Not applicable 2, Phase 2 2, Phase 1/2 1) 2025: 3 trials (Observational 1, Not applicable 1, Phase 2 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 2
2025 3
2024 7
2023 6
2022 1
2021 2
2020 2
2019 1
2017 1
2016 1

No forecast is made for this condition: it averages 4.0 trial starts a year over the five years to September, under the 5 a year the method needs.

Prediction, not a registry value: median of 36 months from start to primary completion across 8 trials still running at the 2026-10-09 snapshot; registered median of 29 months across 21 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Ototoxicity trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 2
Phase 1/2 2
Phase 2 10
Phase 2/3 2
Phase 3 3
Phase 4 2
Not applicable 14
Observational 14

How many Ototoxicity trials are recruiting? (8)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 4
Recruiting 11
Active, not recruiting 2
Completed 20
Suspended 1

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Ototoxicity trials? (4)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Children's Oncology Group 2
Sound Pharmaceuticals, Incorporated 2
VA Office of Research and Development 2
Decibel Therapeutics 1

Which drugs are being tested for Ototoxicity? (1)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Sodium Thiosulfate 4

Interventions as named in the registry (14)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
N Acetylcysteine 4
Cisplatin 1 3
N Acetyl Cysteine 2
Dexamethasone/Dexamethasone acetate 2
Adjuvant Therapy 2

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Ototoxicity trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Febrile neutropenia 12 1
Neutrophil count decreased 10 1
Platelet count decreased 8 1
White blood cell decreased 8 1
Anemia 7 1

Which publications cover Ototoxicity? (18)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Awareness about the risk of hearing loss after ototoxic treatments in Swiss childhood cancer survivors. Patient education and counseling 2025 Yes
Intraarticular vancomycin decreased the risk of acute postoperative periprosthetic joint infection without increasing complication in primary total joint arthroplasty-a prospective study. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2023 Yes
Vestibular Implantation Can Work Even After More Than 20 Years of Bilateral Vestibular Hypofunction. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 2023 Yes
Cisplatin-Induced Ototoxicity: A Concise Review of the Burden, Prevention, and Interception Strategies. JCO oncology practice 2023 Yes
Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: A systematic review and meta-analysis. Cancer epidemiology 2022 Yes

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.

Browse all condition evidence pages